NASDAQ:INSM - Nasdaq - US4576693075 - Common Stock - Currency: USD
NASDAQ:INSM (3/3/2025, 3:53:07 PM)
75.97
-5.58 (-6.84%)
The current stock price of INSM is 75.97 USD. In the past month the price increased by 6.89%. In the past year, price increased by 190.63%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.88 | 373.43B | ||
AMGN | AMGEN INC | 15.62 | 166.25B | ||
GILD | GILEAD SCIENCES INC | 25.1 | 144.20B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1667.79 | 124.25B | ||
REGN | REGENERON PHARMACEUTICALS | 15.03 | 75.00B | ||
ARGX | ARGENX SE - ADR | 242.06 | 37.95B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.26B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.72B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.14B | ||
BIIB | BIOGEN INC | 8.63 | 20.72B | ||
NTRA | NATERA INC | N/A | 18.82B | ||
GMAB | GENMAB A/S -SP ADR | 24.62 | 14.54B |
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 912 full-time employees. The firm's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
INSMED INC
700 Us Highway 202/206
Bridgewater NEW JERSEY 08807 US
CEO: William H. Lewis
Employees: 912
Company Website: https://insmed.com/
Investor Relations: https://investor.insmed.com/index
Phone: 19089779900
The current stock price of INSM is 75.97 USD. The price decreased by -6.84% in the last trading session.
The exchange symbol of INSMED INC is INSM and it is listed on the Nasdaq exchange.
INSM stock is listed on the Nasdaq exchange.
23 analysts have analysed INSM and the average price target is 92.77 USD. This implies a price increase of 22.11% is expected in the next year compared to the current price of 75.97. Check the INSMED INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INSMED INC (INSM) has a market capitalization of 13.59B USD. This makes INSM a Large Cap stock.
INSMED INC (INSM) currently has 912 employees.
INSMED INC (INSM) has a support level at 80.54. Check the full technical report for a detailed analysis of INSM support and resistance levels.
The Revenue of INSMED INC (INSM) is expected to grow by 37.17% in the next year. Check the estimates tab for more information on the INSM EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
INSM does not pay a dividend.
INSMED INC (INSM) will report earnings on 2025-05-07.
INSMED INC (INSM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.58).
The outstanding short interest for INSMED INC (INSM) is 8.23% of its float. Check the ownership tab for more information on the INSM short interest.
ChartMill assigns a technical rating of 10 / 10 to INSM. When comparing the yearly performance of all stocks, INSM is one of the better performing stocks in the market, outperforming 98.01% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to INSM. Both the profitability and financial health of INSM have multiple concerns.
Over the last trailing twelve months INSM reported a non-GAAP Earnings per Share(EPS) of -5.58. The EPS decreased by -4.59% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -45.12% | ||
ROE | -320.2% | ||
Debt/Equity | 3.95 |
ChartMill assigns a Buy % Consensus number of 85% to INSM. The Buy consensus is the average rating of analysts ratings from 23 analysts.
For the next year, analysts expect an EPS growth of 16.18% and a revenue growth 37.17% for INSM